Inovio Pharmaceuticals recruited 40 healthy adults aged 18-50 to take part in their phase I trial of vaccine candidate INO-4800. Participants were given two doses of the vaccine 4 weeks apart - 94% of total participants experienced overall immunological response rates and no adverse events by week 8. The trial will be expanded to include older adults and move to phase II/III launching over the coming months. With 21 strategically located global depots, over 20 years of experience, and a delivery rate of 99.9%, Yourway is the perfect partner to push clinical trials forward.